文献速递腹部MR

利用生成对抗网络在探索性动物研究中降低MRI对比剂剂量

Contrast Agent Dose Reduction in MRI Utilizing a Generative Adversarial Network in an Exploratory Animal Study.
PubMed 文献 · Invest Radiol · 2023-01-12

在20只健康哥廷根小型猪中行120次MRI检查,分别使用低剂量(0.005 mmol/kg)与标准剂量(0.025 mmol/kg)钆塞酸二钠,训练生成对抗网络将低剂量图像转换为虚拟标准剂量图像。虚拟标准剂量与标准剂量的血管及肝实质对比噪声比无显著差异,视觉图灵测试中3名放射科顾问医师认为两者所见一致的比例中位数为100%。

要点

  • 低剂量0.005 mmol/kg钆塞酸二钠经生成对抗网络转换后,血管与肝实质对比噪声比接近标准剂量0.025 mmol/kg。
  • 动态期及肝胆期虚拟标准剂量与标准剂量的对比噪声比无显著差异,视觉图灵测试中两者所见一致的比例中位数为100%。
  • 放射科顾问医师鉴别标准剂量序列的中位数仅54.5%,提示虚拟增强图像主观相似度高。

核心结论

  • 在健康哥廷根小型猪的可行性研究中,基于生成对抗网络的虚拟对比增强可从低剂量数据重建动态期和肝胆期标准剂量图像的表现,钆对比剂剂量降低80%,但临床实施前需在病变动物中进一步验证网络能否正确显示病变。

研究设计与样本

  • 探索性动物研究,20只健康哥廷根小型猪共行120次MRI检查,分6个不同场合进行,50%为低剂量(0.005 mmol/kg钆塞酸二钠)和50%为标准剂量(0.025 mmol/kg),包括动脉期、门静脉期、静脉期和肝胆期(20分钟、30分钟);因检查不完整排除1只动物,随机选3只(18次检查)用于验证,其余16只(96次检查)用于训练生成对抗网络实现低剂量到标准剂量的图像转换。

关键影像表现/征象

  • 动态期血管对比噪声比(均值±标准差):低剂量17.6±6.0,虚拟标准剂量41.8±9.7,标准剂量48.4±12.2。
  • 动态期肝实质对比噪声比(均值±标准差):低剂量20.2±5.9,虚拟标准剂量28.3±6.9,标准剂量29.5±7.2。
  • 肝胆期肝实质对比噪声比(均值±标准差):低剂量22.8±6.2,虚拟标准剂量33.2±6.1,标准剂量37.0±9.1。

诊断标准与关键数值

  • 动态期血管和肝实质合并对比噪声比从低剂量到虚拟标准剂量显著升高(血管P<0.0001,实质P=0.0002),虚拟标准剂量与标准剂量间无显著差异。
  • 肝胆期肝实质合并对比噪声比从低剂量到虚拟标准剂量(P<0.0001)和标准剂量(P<0.0001)均显著升高,虚拟标准剂量与标准剂量间无显著差异。
  • 视觉图灵测试中,3名放射科顾问医师在盲法下判断标准剂量与虚拟标准剂量序列所见一致的比例中位数为100%,识别出标准剂量序列的比例中位数为54.5%。

局限性

  • 本研究为健康哥廷根小型猪的可行性研究,临床实施前需在病变动物中进一步研究以验证网络能否正确显示病变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The aim of this study is to use virtual contrast enhancement to reduce the amount of hepatobiliary gadolinium-based contrast agent in magnetic resonance imaging with generative adversarial networks (GANs) in a large animal model.

METHODS: With 20 healthy Göttingen minipigs, a total of 120 magnetic resonance imaging examinations were performed on 6 different occasions, 50% with reduced (low-dose; 0.005 mmol/kg, gadoxetate) and 50% standard dose (normal-dose; 0.025 mmol/kg). These included arterial, portal venous, venous, and hepatobiliary contrast phases (20 minutes, 30 minutes). Because of incomplete examinations, one animal had to be excluded. Randomly, 3 of 19 animals were selected and withheld for validation (18 examinations). Subsequently, a GAN was trained for image-to-image conversion from low-dose to normal-dose (virtual normal-dose) with the remaining 16 animals (96 examinations). For validation, vascular and parenchymal contrast-to-noise ratio (CNR) was calculated using region of interest measurements of the abdominal aorta, inferior vena cava, portal vein, hepatic parenchyma, and autochthonous back muscles. In parallel, a visual Turing test was performed by presenting the normal-dose and virtual normal-dose data to 3 consultant radiologists, blinded for the type of examination. They had to decide whether they would consider both data sets as consistent in findings and which images were from the normal-dose study.

RESULTS: The pooled dynamic phase vascular and parenchymal CNR increased significantly from low-dose to virtual normal-dose (pooled vascular: P < 0.0001, pooled parenchymal: P = 0.0002) and was found to be not significantly different between virtual normal-dose and normal-dose examinations (vascular CNR [mean ± SD]: low-dose 17.6 ± 6.0, virtual normal-dose 41.8 ± 9.7, and normal-dose 48.4 ± 12.2; parenchymal CNR [mean ± SD]: low-dose 20.2 ± 5.9, virtual normal-dose 28.3 ± 6.9, and normal-dose 29.5 ± 7.2). The pooled parenchymal CNR of the hepatobiliary contrast phases revealed a significant increase from the low-dose (22.8 ± 6.2) to the virtual normal-dose (33.2 ± 6.1; P < 0.0001) and normal-dose sequence (37.0 ± 9.1; P < 0.0001). In addition, there was no significant difference between the virtual normal-dose and normal-dose sequence. In the visual Turing test, on the median, the consultant radiologist reported that the sequences of the normal-dose and virtual normal-dose are consistent in findings in 100% of the examinations. Moreover, the consultants were able to identify the normal-dose series as such in a median 54.5% of the cases.

CONCLUSIONS: In this feasibility study in healthy Göttingen minipigs, it could be shown that GAN-based virtual contrast enhancement can be used to recreate the image impression of normal-dose imaging in terms of CNR and subjective image similarity in both dynamic and hepatobiliary contrast phases from low-dose data with an 80% reduction in gadolinium-based contrast agent dose. Before clinical implementation, further studies with pathologies are needed to validate whether pathologies are correctly represented by the network.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Haubold J, Jost G, Theysohn JM, et al. Contrast Agent Dose Reduction in MRI Utilizing a Generative Adversarial Network in an Exploratory Animal Study. Invest Radiol. 2023. PMID: 36728299. doi:10.1097/RLI.0000000000000947

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。